This week, we’ll be discussing research highlights in lung cancer presented at the ESMO Congress 2019, including the FLAURA trial of osimertinib in EGFR-mutated non–small cell lung cancer; the CheckMate 227 of nivolumab plus ipilimumab vs chemotherapy in non–small cell lung cancer with a PD-L1 expression of 1% or more; and the ASCEND-7 trial of ceritinib for ALK-positive non–small cell lung cancer that has spread to the brain.

Coverage of stories discussed this week on ascopost.com:

ESMO 2019: Overall Survival With Immunotherapy Doublet vs Chemotherapy in Advanced NSCLC

ESMO 2019: ASCEND-7: Ceritinib for Patients With ALK-Positive NSCLC Metastatic to the Brain